New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment
Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected to complete in the fourth quarter of 2020.
The acquisition will help Sanofi transform its R & D and accelerate the discovery and manufacturing of novel medications in areas with significant unmet needs.
Principia’s experimental Bruton tyrosine kinase (BTK) inhibitors will help Sanofi leverage the inhibitors’ ability to block the signaling pa...
